• Skip to primary navigation
  • Skip to content
  • Skip to footer
Gynesonics

Gynesonics

Advancing technology. Improving women's lives.

  • Our Company
    • About Us
    • Careers
    • Compliance
  • Our People
    • Management
    • Board of Directors
    • Investors
  • Our Technology
    • The Sonata System
    • Indications and Safety
    • Instructions for Use
    • Request for Medical or Scientific Information
  • Our News
    • Press Releases
    • In the News
    • Publications
    • 2022 Events
  • Contact Us

Press Releases

Oct 5, 2021

Gynesonics Announces First Office-Based Sonata Procedure in the State of Texas

Dr. John Thoppil, Current President of the Texas Association of Obstetricians and Gynecologists (TAOG), Performs Sonata Procedure in Austin Redwood City, CA, October 5, 2021 – Gynesonics®, a women’s healthcare company focused on the development of minimally invasive solutions for symptomatic uterine fibroids, announced today that Dr. John Thoppil is the first physician in the […]

Sep 29, 2021

Gynesonics Names Robert Brown Chief Financial Officer

Redwood City, CA, September 29, 2021 – Gynesonics®, a women’s healthcare company focused on the development of minimally invasive solutions for symptomatic uterine fibroids, announced today that Robert Brown has joined the company as Chief Financial Officer, starting immediately. Mr. Brown’s background includes significant experience successfully scaling business in healthcare, including medical devices. He most […]

Sep 16, 2021

Gynesonics Announces FDA Clearance of Next Generation Sonata System

The Only Transcervical, Incisionless System for Radiofrequency Ablation of Fibroids Provides New Benefits through Features Such as Increased Range of Ablation Sizes, a New User Interface, and Validation of Additional Low Temperature Hospital Reprocessing Systems Redwood City, CA, September 16, 2021 – Gynesonics®, a women’s healthcare company focused on the development of minimally invasive solutions […]

Sep 14, 2021

Gynesonics Announces Anthem, the Second Largest Healthcare Payer in the U.S., Issues Medical Necessity Coverage for the Treatment of Symptomatic Uterine Fibroids with the Sonata Procedure

 Anthem’s decision significantly increases nationwide access for Sonata Redwood City, CA, September 14, 2021 – Gynesonics®, a women’s healthcare company focused on the development of minimally invasive solutions for symptomatic uterine fibroids, announced Anthem, Inc., the largest managed health care company in the Blue Cross Blue Shield Association, has provided positive payer coverage for the […]

Aug 11, 2021

Gynesonics Announces Expert Group of European Gynecologic Surgeons Publishes Consensus on the Broad Use of the Sonata Technology in a New Treatment Strategy for Symptomatic Fibroids

The Combined Clinical Experience of Over 1000 Sonata Procedures, Across Three Countries, Drives New Recommendation for Sonata as a First Line Therapy for Fibroid Treatment Redwood City, CA, August 11, 2021 – Gynesonics®, a women’s healthcare company focused on the development of minimally invasive solutions for symptomatic uterine fibroids, announced today a group of 12 […]

Jun 10, 2021

Gynesonics Announces Positive Payer Coverage Issued by Blue Cross Blue Shield of Florida (Florida Blue) for the Sonata Treatment

 Florida Blue is the Largest Healthcare Payer in that State Redwood City, CA, June 11, 2021 – Gynesonics®, a women’s healthcare company focused on the development of minimally invasive solutions for symptomatic uterine fibroids, announced today Blue Cross Blue Shield of Florida (Florida Blue) has released a coverage policy for its Sonata® Procedure.1  The addition […]

Jun 7, 2021

Gynesonics Appoints David Pacitti to Board Chair

Current President and Head of Siemens Healthineers in The Americas Brings Strong Commercial Experience to the Board of Directors  Karen Talmadge, Ph.D., Remains as Independent Board Member, Retaining Key Strengths and Experience for Gynesonics Redwood City, CA, June 7, 2021 – Gynesonics®, a women’s healthcare company focused on the development of minimally invasive solutions for […]

Jun 3, 2021

Gynesonics Announces Positive Coverage Policy Decision Published by Cigna for Treatment of Uterine Fibroids with the Sonata System

 The national policy covers approximately 15 million lives in 48 states and Washington D.C. for this minimally invasive, uterine-preserving and incision-free treatment Redwood City, CA, June 3, 2021 – Gynesonics®, a women’s healthcare company focused on the development of minimally invasive solutions for symptomatic uterine fibroids, announced today that Cigna has released a national coverage […]

Jun 1, 2021

New Guidance from the American College of Obstetricians and Gynecologists for Fibroid Management Supports Incisionless Transcervical Radiofrequency Ablation as a Uterus-Preserving Treatment Option

Additionally, an expert physician panel in Europe reached consensus and published a new recommended fibroid treatment algorithm with transcervical radiofrequency ablation (Sonata) at the forefront Redwood City, CA, June 1, 2021 – Gynesonics®, a women’s healthcare company focused on the development of minimally invasive solutions for symptomatic uterine fibroids, announced the publication of guidelines by […]

Apr 15, 2021

Gynesonics Announces Publication of SAGE Global Registry Preliminary Results: Real-World Usage Corroborates the Safety and Applicability of Sonata Transcervical Fibroid Ablation

The initial results of the first 160 treated women in the Transcervical Radiofrequency Ablation of Uterine Fibroids Global Registry (SAGE) show the broad applicability of Transcervical Fibroid Ablation performed by the Sonata System to a wide range of fibroid types and sizes while maintaining an excellent safety profile Redwood City, CA, April 15, 2021 – […]

  • 1
  • 2
  • 3
  • …
  • 6
  • Next »

Footer

  • Privacy Policy
  • Terms of Use
  • Patents
  • Safety Information

© Copyright 2023 Gynesonics · All Rights Reserved · WS 05198 Rev. J

This website uses cookies to provide you with the best browsing experience.

Find out more or adjust your settings.

Gynesonics
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.

Show details
Name Provider Purpose Expiration
moove_gdpr_popup Gynesonics via Moove GDPR Plugin This is used to save your cookie settings for this website. 12 months
__cf_bm Cloudflare The __cf_bm cookie is a cookie necessary to support Cloudflare Bot Management. As part of their bot management service, this cookie helps manage incoming traffic that matches criteria associated with bots. Cookie is set on websites using Cloudfare and it is related to rate limiting policies. less than 12m
Analytics Cookies

This website uses analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.

Keeping this cookie enabled helps us to improve our website.

Please enable Strictly Necessary Cookies first so that we can save your preferences!

Show details
Name Provider Purpose Expiration
_ga, _gat, _gid, _ga_* Google Analytics These cookies enable analytics features in our suite (e.g., distinguish users, remember traffic information, and determine the start and end of a session). They are set for analytics measures on our website. We can take a timestamp of your website visit, track the source (e.g. search engine) you used to access our website, and the number of times you visit our website. 1-12 months
_gcl_au, _gat_gtag_UA_* Google Tag Manager These cookies helps us to enable functional requests on our website, such as the communications between our website and resources such as style, fonts, and images. As a cookie related to our Tag Manager, it collects your interaction with our resources (e.g. clicks and views) to help us understand your behavior on our website as well as to improve our aggregated analysis from interactions and campaigns. 1-12 months